Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

3347 Analyst Ratings

Moderate Buy

4 Buy

0 Hold

1 Sell

Based on 5 analysts giving stock ratings to

Hangzhou

Tigermed Consulting Co., Ltd. Class H

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

3347 Stock 12 Month Forecast

Average Price Target

HK$52.88

▲(3.78% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Hangzhou Tigermed Consulting Co., Ltd. Class H in the last 3 months. The average price target is HK$52.88 with a high forecast of HK$63.40 and a low forecast of HK$38.00. The average price target represents a 3.78% change from the last price of HK$50.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"HK$25","64":"HK$64","34.75":"HK$34.8","44.5":"HK$44.5","54.25":"HK$54.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":63.40000002292544,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$63.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52.8750226928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$52.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.0000000137408,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,34.75,44.5,54.25,64],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.54,44.14461538637888,45.74923077275776,47.35384615913664,48.95846154551552,50.5630769318944,52.16769231827328,53.772307704652164,55.37692309103104,56.98153847740992,58.5861538637888,60.190769250167676,61.79538463654656,{"y":63.40000002292544,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.54,43.335001745599996,44.1300034912,44.9250052368,45.7200069824,46.515008728,47.3100104736,48.1050122192,48.9000139648,49.6950157104,50.490017456000004,51.2850192016,52.0800209472,{"y":52.8750226928,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.54,42.190769231826216,41.841538463652434,41.492307695478644,41.14307692730486,40.79384615913108,40.444615390957296,40.095384622783506,39.74615385460972,39.39692308643594,39.04769231826216,38.69846155008837,38.349230781914585,{"y":38.0000000137408,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.553,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.031,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":33.578,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.892,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.535,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.247,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.54,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$63.40

Average Price TargetHK$52.88

Lowest Price TargetHK$38.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chris Pan

Goldman Sachs

HK$62.1→HK$63.4

Buy

24.44%

Upside

Reiterated

11/21/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Clinigence Holdings (NASDAQ: NUTX), CSPC Pharmaceutical Group (Other OTC: CHJTF) and Hangzhou Tigermed Consulting Co., Ltd. Class H (Frankfurt: DE:5HZ1)

Linda Shu

HSBC

HK$51.1→HK$54

Buy

5.99%

Upside

Reiterated

11/05/25

HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Michael Luo CFA

CLSA

HK$58.9→HK$52.1

Buy

2.26%

Upside

Reiterated

10/30/25

Yang Huang

J.P. Morgan

HK$37→HK$38

Sell

-25.42%

Downside

Reiterated

10/29/25

J.P. Morgan Sticks to Their Sell Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

UBS

Not Ranked

UBS

HK$57.1

Buy

12.07%

Upside

Reiterated

10/28/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

HK$51

Buy

0.10%

Upside

Reiterated

09/01/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$57.5

Buy

12.86%

Upside

Reiterated

08/29/25

David Li

Bank of America Securities

HK$56

Buy

9.91%

Upside

Reiterated

08/29/25

Ruili Bian

Citi

HK$37→HK$73

Buy

43.28%

Upside

Reiterated

07/14/25

Citi Reaffirms Their Buy Rating on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$50

Buy

-1.86%

Downside

Reiterated

07/04/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$38

Sell

-25.42%

Downside

Reiterated

06/12/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chris Pan

Goldman Sachs

HK$62.1→HK$63.4

Buy

24.44%

Upside

Reiterated

11/21/25

Linda Shu

HSBC

HK$51.1→HK$54

Buy

5.99%

Upside

Reiterated

11/05/25

HSBC Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Michael Luo CFA

CLSA

HK$58.9→HK$52.1

Buy

2.26%

Upside

Reiterated

10/30/25

Yang Huang

J.P. Morgan

HK$37→HK$38

Sell

-25.42%

Downside

Reiterated

10/29/25

J.P. Morgan Sticks to Their Sell Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

UBS

Not Ranked

UBS

HK$57.1

Buy

12.07%

Upside

Reiterated

10/28/25

Unknown Analyst

Bank of China

Not Ranked

Bank of China

HK$51

Buy

0.10%

Upside

Reiterated

09/01/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$57.5

Buy

12.86%

Upside

Reiterated

08/29/25

David Li

Bank of America Securities

HK$56

Buy

9.91%

Upside

Reiterated

08/29/25

Ruili Bian

Citi

HK$37→HK$73

Buy

43.28%

Upside

Reiterated

07/14/25

Citi Reaffirms Their Buy Rating on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$50

Buy

-1.86%

Downside

Reiterated

07/04/25

Unknown Analyst

Daiwa

Not Ranked

Daiwa

HK$38

Sell

-25.42%

Downside

Reiterated

06/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hangzhou Tigermed Consulting Co., Ltd. Class H

1 Month

xxx

Success Rate

4/4 ratings generated profit

Average Return

+13.23%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +13.23% per trade.

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

+8.43%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +8.43% per trade.

1 Year

David LiBank of America Securities

Success Rate

2/2 ratings generated profit

Average Return

+25.85%

reiterated a buy rating 5 months ago

Copying David Li's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +25.85% per trade.

2 Years

xxx

Success Rate

4/7 ratings generated profit

Average Return

+18.30%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +18.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3347 Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 3347 has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 3347 average Analyst price target in the past 3 months is 52.88.

Each month's total comprises the sum of three months' worth of ratings.

3347 Financial Forecast

3347 Earnings Forecast

Next quarter’s earnings estimate for 3347 is HK$0.25 with a range of -HK$0.11 to HK$0.61. The previous quarter’s EPS was HK$0.81. 3347 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 3347 has Performed in-line its overall industry.

3347 Sales Forecast

Next quarter’s sales forecast for 3347 is HK$1.89B with a range of HK$1.89B to HK$1.89B. The previous quarter’s sales results were HK$1.94B. 3347 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 3347 has Performed in-line its overall industry.

3347 Stock Forecast FAQ

What is HK:3347’s average 12-month price target, according to analysts?

Based on analyst ratings, Hangzhou Tigermed Consulting Co., Ltd. Class H’s 12-month average price target is 52.88.

What is HK:3347’s upside potential, based on the analysts’ average price target?

Hangzhou Tigermed Consulting Co., Ltd. Class H has 3.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hangzhou Tigermed Consulting Co., Ltd. Class H a Buy, Sell or Hold?

Hangzhou Tigermed Consulting Co., Ltd. Class H has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 0 hold ratings and 1 sell ratings.

What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s share price target?

The average share price target for Hangzhou Tigermed Consulting Co., Ltd. Class H is 52.88. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$63.40 ,and the lowest forecast is HK$38.00. The average share price target represents 3.78% Increase from the current price of HK$50.95.

What do analysts say about Hangzhou Tigermed Consulting Co., Ltd. Class H?

Hangzhou Tigermed Consulting Co., Ltd. Class H’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Hangzhou Tigermed Consulting Co., Ltd. Class H?

To buy shares of HK:3347, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) Stock Forecast & Price Target

3347 Analyst Ratings

3347 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hangzhou Tigermed Consulting Co., Ltd. Class H

3347 Analyst Recommendation Trends

3347 Financial Forecast

3347 Earnings Forecast

3347 Sales Forecast

3347 Stock Forecast FAQ

Detailed List of Analyst Forecasts